New costing templates available
This follows feedback that certain amendments would improve clarity and usefulness of the templates.
The changes to cost impacts are:
- dabigatran has reduced in national cost cost impact for England from £25.1m to £21.6m (range of £55.4m to a saving of £12.0m).
- rivaroxaban has reduced in national cost impact for England from £10.2m to £9.9m (range of £39.8 to a saving of £19.9m)
The templates are based on a series of assumptions and for some variables it is hard to obtain absolute estimates. A sensitivity analysis shows this variation and the cost impact is in within ranges. It is important for users to input local data to tailor the templates to obtain more appropriate local cost impacts.
25 October 2012